Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?

Core Viewpoint - Incyte Corporation (INCY) is expected to exceed revenue and earnings estimates for Q4 2025, with projected revenues of $1.35 billion and earnings of $1.94 per share [2][6]. Revenue Drivers - The primary revenue source for Incyte is the sales of its lead drug, Jakafi (ruxolitinib), which is anticipated to continue its strong performance across all approved indications [3][4]. - Jakafi's fourth-quarter sales are estimated at $799.3 million, with additional royalty revenues expected from Novartis due to higher Jakavi sales outside the U.S. [4][6]. - Other contributing factors to revenue include growth in Opzelura sales, which are projected at $196.5 million, and sales from other drugs like Minjuvi, Pemazyre, and Iclusig [8][12]. Recent Developments - Incyte's recent approval of Monjuvi for a new cancer indication is likely to enhance its sales, with the drug also receiving approval in the EU and Japan [10][12]. - The launch of Niktimvo, which recorded $45.8 million in sales in Q3 2025, is another significant development for the company [13][14]. Financial Performance - Incyte's stock has increased by 31.4% over the past six months, compared to the industry growth of 43.5% [5]. - The company has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 14.35% [15]. Earnings Expectations - The Earnings Surprise Prediction model indicates a likelihood of an earnings beat for Incyte, with an Earnings ESP of +3.69% [16][17].